#China #Shanghai #biopharmaceuticals #Mabwell #AACR

Mabwell's Presentation at AACR 2025

Mabwell, a pioneering biopharmaceutical firm based in Shanghai, has announced its participation in the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled to take place from April 25 to April 30 in Chicago, USA. The company will showcase the findings from six significant studies, which highlight its commitment to advancing cancer treatment methodologies.

The AACR Annual Meeting stands as one of the world's largest gatherings dedicated to cancer research, making it an exciting opportunity for Mabwell to share its innovations with the global scientific community. The abstracts detailing these studies have already been made available on the AACR's official platform, illustrating the breadth of research and development efforts underway at Mabwell.

Highlights of the Studies

1. B7-H3-Targeting Antibody-Drug Conjugate (7MW3711)
- Abstract Number: 830
- Session Date: April 27, 2025
- Time: 2:00 PM - 5:00 PM
- This study investigates the synergy between a B7-H3-targeting antibody-drug conjugate and PARP inhibitors, revealing promising results in enhancing antitumor activity in cancers that express B7-H3.

2. Camptothecin Analog MF6
- Abstract Number: 5733
- Session Date: April 29, 2025
- Time: 2:00 PM - 5:00 PM
- Researchers present the design and synthesis of a novel camptothecin analog, MF6, created for potential use in site-specific antibody-drug conjugates.

3. Novel CLDN1-Targeting Antibody-Drug Conjugates (MW-C01/C02)
- Abstract Number: 1573
- Session Date: April 28, 2025
- Time: 9:00 AM - 12:00 PM
- This presentation will discuss compelling preclinical results showcasing the anti-tumor efficacy and safety profiles of the MW-C01/C02 products.

4. Bispecific T-Cell Engager (2MW7061)
- Abstract Number: 2116
- Session Date: April 28, 2025
- Time: 9:00 AM - 12:00 PM
- This study provides insights into a novel bispecific T-cell engager designed to target monocytic acute myeloid leukemia, focusing on therapeutic advancements in blood-related cancers.

5. Innovative T Cell Engager Platform
- Abstract Number: 2866
- Session Date: April 28, 2025
- Time: 2:00 PM - 5:00 PM
- This research discusses optimizing a T cell engager platform for improved targeting of both hematologic and solid tumors.

6. Cadherin 17-Targeting ADC (7MW4911)
- Abstract Number: 5466
- Session Date: April 29, 2025
- Time: 2:00 PM - 5:00 PM
- The efficacy of the novel cadherin 17-targeting antibody-drug conjugate is highlighted through preclinical models focused on gastrointestinal cancers.

About Mabwell

Mabwell, listed on the Shanghai Stock Exchange (688062.SH), circles around the vision of providing advanced and accessible therapeutic options. Their research and development framework covers all phases, from target discovery right through to manufacturing transformation. The company boasts a diverse portfolio with 16 pipeline products spanning various therapeutic areas, including oncology and immunology. Three of these products have received approval and are currently marketed, while several others are progressing through critical clinical trials.

Mabwell's state-of-the-art manufacturing facilities in Taizhou and Shanghai are equipped to comply with international GMP standards, reflecting its commitment to quality and regulatory adherence. The company’s overarching mission, "Explore Life, Benefit Health," embodies its dedication to impactful medical therapies.

Forward-Looking Statements

Mabwell aims to maintain transparency about its activities, and the information presented relates to anticipatory statements regarding the outcomes of their studies and products. It is essential to recognize the inherent risks and uncertainties associated with drug development, which may affect actual results.


In conclusion, with their exciting lineup for the AACR 2025, Mabwell stands firmly at the forefront of biopharmaceutical innovation, poised to make significant contributions to cancer research and treatment.